These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21693019)

  • 41. Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4.
    Al Ashgar H; Helmy A; Khan MQ; Al Kahtani K; Al Quaiz M; Rezeig M; Kagevi I; Alshehri A; Al Kalbani A; Al Swat K; Dahab S; Elkum N; Al Fadda M
    Ann Saudi Med; 2009; 29(1):4-14. PubMed ID: 19139619
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.
    Welzel TM; Morgan TR; Bonkovsky HL; Naishadham D; Pfeiffer RM; Wright EC; Hutchinson AA; Crenshaw AT; Bashirova A; Carrington M; Dotrang M; Sterling RK; Lindsay KL; Fontana RJ; Lee WM; Di Bisceglie AM; Ghany MG; Gretch DR; Chanock SJ; Chung RT; O'Brien TR;
    Hepatology; 2009 Jun; 49(6):1847-58. PubMed ID: 19434718
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
    Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M
    Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection: A Retrospective Cohort Study.
    Naing C; Sitt T; Aung AT; Aung K
    Medicine (Baltimore); 2015 Jul; 94(30):e1234. PubMed ID: 26222859
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe.
    Urbanek P; Oltman M; Ivanovski L; Rehák V; Messinger D; Tietz A; Husa P
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(11):1004-10. PubMed ID: 21904204
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response.
    Craxi A; Koutsounas S; Ogurtsov P; Chemello L; Maticic M; Torras J; Diago M; Tartaglione MT; Witthoeft T; Yu X; Faruqi R; Chaudhri E; Pedicone LD; Zuckerman E
    J Viral Hepat; 2012 Feb; 19(2):e120-5. PubMed ID: 22239509
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
    Crespo M; Esteban JI; Ribera E; Falco V; Sauleda S; Buti M; Esteban R; Guardia J; Ocaña I; Pahissa A
    AIDS; 2007 Feb; 21(4):477-81. PubMed ID: 17301566
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Similar treatment response to peginterferon and ribavirin in Asian and Caucasian patients with chronic hepatitis C.
    Vutien P; Nguyen NH; Trinh HN; Li J; Garcia RT; Garcia G; Nguyen KK; Nguyen HA; Levitt BS; Keeffe EB; Nguyen MH
    Am J Gastroenterol; 2010 May; 105(5):1110-5. PubMed ID: 19904247
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
    Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
    J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection.
    Pedersen C; Alsiö Å; Lagging M; Langeland N; Färkkilä M; Buhl MR; Mørch K; Westin J; Sangfelt P; Norkrans G; Christensen PB;
    J Viral Hepat; 2011 Apr; 18(4):245-51. PubMed ID: 20384961
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment.
    Ogawa E; Furusyo N; Toyoda K; Taniai H; Otaguro S; Kainuma M; Murata M; Sawayama Y; Hayashi J
    BMC Gastroenterol; 2010 Apr; 10():38. PubMed ID: 20398383
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Short-term therapy with pegylated interferon plus ribavirin for the chronic hepatitis C genotype 2 patients].
    Jung EU; Park JH; Pae KI; Kang SW; Park SJ; Jee SR; Park ET; Lee YJ; Lee SH; Seol SY
    Korean J Hepatol; 2007 Sep; 13(3):341-8. PubMed ID: 17898550
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007).
    Bourlière M; Ouzan D; Rosenheim M; Doffoël M; Marcellin P; Pawlotsky JM; Salomon L; Fagnani F; Rouanet S; Pinta A; Vray M
    Antivir Ther; 2012; 17(1):101-10. PubMed ID: 22267474
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.
    Jacobson IM; Marcellin P; Zeuzem S; Sulkowski MS; Esteban R; Poordad F; Bruno S; Burroughs MH; Pedicone LD; Boparai N; Deng W; DiNubile MJ; Gottesdiener KM; Brass CA; Albrecht JK; Bronowicki JP
    Hepatology; 2012 Aug; 56(2):567-75. PubMed ID: 22619063
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin.
    Grasso A; Malfatti F; De Leo P; Martines H; Fabris P; Toscanini F; Anselmo M; Menardo G
    J Hepatol; 2009 Dec; 51(6):984-90. PubMed ID: 19695729
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C.
    Ide T; Hino T; Ogata K; Miyajima I; Kuwahara R; Kuhara K; Sata M
    Am J Gastroenterol; 2009 Jan; 104(1):70-5. PubMed ID: 19098852
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response.
    Gordon SC; Reddy KR; Jacobson IM; Poordad F; Bronowicki JP; Bacon B; Buti M; Hu KQ; Pedicone LD; Burroughs M; Brass CA; Albrecht JK; Lawitz EJ
    J Clin Gastroenterol; 2014; 48(5):435-43. PubMed ID: 24177376
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy.
    Yoshida EM; Sherman M; Bain VG; Cooper CL; Deschênes M; Marotta PJ; Lee SS; Krajden M; Witt-Sullivan H; Bailey RJ; Usaty C; Peltekian K;
    Can J Gastroenterol; 2009 Mar; 23(3):180-4. PubMed ID: 19319382
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a.
    Zhou YQ; Wang XH; Hong GH; Zhu Y; Zhang XQ; Hu YJ; Mao Q
    J Viral Hepat; 2011 Aug; 18(8):595-600. PubMed ID: 21105968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.